Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Glioma & glioblastoma, drawn from the whole corpus: 150 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
14 medicines on record are linked to one of the types below rather than to Glioma & glioblastoma itself. Grouped by the type that holds them; each list opens that type's own page.
Blood-brain barrier.
Immunologically cold, heterogeneous, infiltrative.
Glioblastoma: no systemic drug has beaten the 2005 standard; getting drugs across the blood-brain barrier is the crux.
No systemic drug has beaten the 2005 chemoradiation standard in a phase 3 trial, though tumour treating fields (EF-14, 2015) and short-course radiotherapy from age 65 (CCTG CE.6, 2017) both added survival; locoregional CAR-T, focused-ultrasound barrier opening and neoantigen vaccines are the current attempts.
MGMT-unmethylated glioblastoma (~60%) gains less from temozolomide than methylated disease, and how much less is still debated; NCCN keeps radiotherapy with temozolomide as an option for this group alongside a clinical trial, and it is the population most current trials are built on.
Blood-brain barrier and diffuse infiltration limit delivery and resection; imaging cannot distinguish progression from pseudoprogression reliably.
Immunotherapy failure: low TMB, T-cell exclusion, dexamethasone, and treatment-induced lymphopenia; neoadjuvant approaches are the only signal.
Antigen heterogeneity and loss (EGFRvIII, IL13Rα2) undermine single-target vaccines, ADCs, and CAR-T.
Diffuse midline glioma has one approved drug, dordaviprone, with a 22% response rate; making those responses last is the open question, and the phase 3 ACTION trial, GD2 CAR-T and convection-enhanced delivery are the attempts on it.
Trial design: single-arm and external-control comparisons (DCVax-L, historical vaccine data) have repeatedly misled the field.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 49 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 1.1 years later, when the FDA's table was read.
Recurrent H3 K27M-mutant diffuse midline glioma, age ≥1 (accelerated)
6 August 2025; first systemic therapy for the disease.
Regorafenib, the first arm, did not improve overall survival in newly diagnosed or recurrent glioblastoma; paxalisib and VAL-083 did not graduate; later arms continue.